Indication
Chronic Myeloid Leukemia
77 clinical trials
86 products
12 drugs
Clinical trial
A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2023-03-03
Product
RadotinibProduct
ImatinibClinical trial
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric ParticipantsStatus: Recruiting, Estimated PCD: 2024-12-07
Product
PonatinibClinical trial
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-01
Product
MGD024Clinical trial
A Phase II, Single-arm Study of De-escalation and Treatment-free Remission in Patients With Chronic Myeloid Leukemia Treated With Nilotinib in First-line Therapy Followed by a Second Attempt After Nilotinib and Asciminib Combination: DANTE StudyStatus: Active (not recruiting), Estimated PCD: 2026-07-31
Product
Orca-TClinical trial
A Phase Ib Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic GraftStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-12-01
Product
ELVN-001Product
NilotinibProduct
AsciminibClinical trial
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.Status: Recruiting, Estimated PCD: 2027-02-15
Product
nilotinibClinical trial
A Phase II, Single Arm, Open Label Study of Treatment-free Remission in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients After Achieving Sustained MR4.5 on NilotinibStatus: Active (not recruiting), Estimated PCD: 2015-11-26
Product
OrcaGraftClinical trial
A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2026-04-01
Product
VodobatinibClinical trial
A Phase II Multi-center, Open Label Study of HQP1351 in Chinese Patients of Chronic Myeloid Leukemia With T315I Mutation in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Product
HS-10382Clinical trial
A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10382 in Patients With Chronic Myeloid Leukemia.Status: Recruiting, Estimated PCD: 2024-12-30
Product
CarcemiaProduct
GlivecClinical trial
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia; a Multicenter, Observational StudyStatus: Recruiting, Estimated PCD: 2024-08-01
Product
HQP1351Product
TERN-701Clinical trial
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Status: Active (not recruiting), Estimated PCD: 2026-08-01
Clinical trial
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2025-11-30
Clinical trial
Post-Marketing Surveillance of Safety and Effectiveness of Iclusig® Tablets in Korean Patients With CML or Ph+ ALL Under the "Risk Management Plan"Status: Active (not recruiting), Estimated PCD: 2022-11-29
Clinical trial
Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREEStatus: Completed, Estimated PCD: 2017-09-20
Product
DasatinibClinical trial
A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including ImatinibStatus: Recruiting, Estimated PCD: 2025-01-29
Clinical trial
A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I MutationStatus: Active (not recruiting), Estimated PCD: 2022-07-22
Clinical trial
A Dose Calibration and Dose Equivalence Pharmacokinetic Study in Healthy Volunteers Comparing IkT-001Pro to Imatinib Mesylate 400mgStatus: Recruiting, Estimated PCD: 2023-12-31
Product
IkT-001ProProduct
Systemic TreatmentClinical trial
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg ImatinibStatus: Completed, Estimated PCD: 2017-11-08
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)Status: Recruiting, Estimated PCD: 2024-01-31
Product
Ascentage Pharma HQP1351Product
BlinatumomabClinical trial
Multicenter Prospective Trial After 1st or 2nd Unsuccessful Treatment Discontinuation in Chronic Myeloid Leukemia ( CML) Estimating the Efficacy of Nilotinib in Inducing the Persistence of Molecular Remission After Stopping TKI a 2nd or 3rd TimeStatus: Active (not recruiting), Estimated PCD: 2026-09-01
Drug
nilotinibClinical trial
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular ResponseStatus: Active (not recruiting), Estimated PCD: 2021-11-08
Clinical trial
Discontinuation of TyrosIne Kinase Inhibitors (ITK) in Chronic Myeloid Leukemia (LMC) and Impact on the Immune System: a Randomized Comparative Study of Two Therapeutic StrategiesStatus: Recruiting, Estimated PCD: 2028-12-01
Product
TKI in CMLClinical trial
Safety And Efficacy Of Tyrosine Kinase Inhibitor Cessation For Chronic Myeloid Leukemia Patients With Stable Molecular Response In A Real World PopulationStatus: Recruiting, Estimated PCD: 2025-11-15
Product
Imatinib MesylateClinical trial
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.Status: Recruiting, Estimated PCD: 2033-07-01
Clinical trial
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Drug
cyclophosphamideProduct
FludarabineClinical trial
Multicenter, Open-label, Phase Ib/II Trial to Evaluate Safety and Efficacy for the Combination of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Myeloid Leukemia PatientsStatus: Terminated, Estimated PCD: 2021-09-24
Product
BosutinibProduct
Bosutinib + AtezolizumabClinical trial
Tyrosine Kinase Inhibitors of BCR/ABL: Pharmacokinetic and Pharmacogenetic Study in Patients Affected by Chronic Myeloid Leukemia. Evaluation of Efficacy and TolerabilityStatus: Recruiting, Estimated PCD: 2024-12-31
Product
Imatinib/NilotinibProduct
ThiotepaDrug
MelphalanProduct
G-csfProduct
MesnaProduct
ATGProduct
TCRα/β+Product
CD19+Product
CD45RA-depleted DLIClinical trial
Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve a Deep Molecular Remission (ALERT CML)Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
Acetylsalicylic acidProduct
Ascimininb + NilotinibProduct
Asciminib + ImatinibProduct
Asciminib + DasatinibClinical trial
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia in Combination With Asciminib and Tyrosine Kinase InhibitorsStatus: Not yet recruiting, Estimated PCD: 2028-08-31
Clinical trial
Collection of Biological Resources During Medical Care of Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase for an Epigenetic Study of Leukemic Stem CellsStatus: Recruiting, Estimated PCD: 2025-05-01
Product
Blood and Bone MarrowClinical trial
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)Status: Recruiting, Estimated PCD: 2026-06-30
Drug
TKIClinical trial
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Product
DecitabineProduct
ListaftoclaxDrug
OlverembatinibClinical trial
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity With BortezomibStatus: Completed, Estimated PCD: 2021-04-06
Product
BortezomibProduct
NK cellsClinical trial
A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-12-31
Product
VactosertibDrug
fludarabineClinical trial
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2026-02-01
Product
BusulfanProduct
TacrolimusProduct
Mycophenolate MofetilClinical trial
CML Pediatric ITK Response According to Molecular Identification at Diagnosis (CML PiramidStatus: Recruiting, Estimated PCD: 2024-01-01
Product
Next Generation SequencingClinical trial
A Phase I/II Clinical Trial of "Off-the-shelf" NK Cell Administration in Combination With Allogeneic SCT to Decrease Disease Relapse in Patients With High-risk Myeloid Malignancies Undergoing Matched Related, Matched Unrelated, One Antigen Mismatched Unrelated, or Haploidentical Stem-cell TransplantationStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic MalignanciesStatus: Withdrawn, Estimated PCD: 2027-04-01
Clinical trial
Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(CML-CP) : A Multicenter, Open-lable, Real World StudyStatus: Recruiting, Estimated PCD: 2025-01-01
Product
FlumatinibDrug
FilgrastimProduct
Mycophenolate mofetilProduct
Total Body IrradiationClinical trial
Phase I Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia: MDS, MDS/MPNs, and MyelofibrosisStatus: Recruiting, Estimated PCD: 2025-09-04
Product
AzacitidineProduct
SelumetinibClinical trial
Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)Status: , Estimated PCD: 2027-10-16
Clinical trial
Activity and Safety of Front-linevenetoclax and Rituximab Association (VeRiTAs) in Young and Fit Patients With Chronic Lymphocytic Leukemia (CLL) and Umutated IGVH and/or Disrupted TP53. A Phase 2 Multicenter StudyStatus: Completed, Estimated PCD: 2021-09-05
Product
VenetoclaxDrug
VarlilumabClinical trial
KISS Study: A Phase II Study of Dasatinib Followed by Imatinib in Newly Diagnosed, Previously Untreated Patients With Chronic Phase CMLStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
CD34 Selected Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning and CD8+ Memory T Cell Infusion For Patients With Myelodysplastic Syndrome, Acute Leukemia, and Chronic Myelogenous LeukemiaStatus: , Estimated PCD: 2025-02-01
Clinical trial
Phase 1a/1b Study of Itacitinib (INCB039110) for Cytokine Release Syndrome Prevention and Minimization of Immunosuppression Following Nonmyeloablative Related Partially HLA-mismatched Peripheral Blood Stem Cell Transplant (PBSCT) With High-dose Posttransplantation Cyclophosphamide in Older Patients (Age 60 Years)Status: Recruiting, Estimated PCD: 2028-03-01
Product
ItacitinibProduct
CD8+ Memory T Cell InfusionClinical trial
This is a Global, Multi-center, Open-label Randomized and Registrational Phase 3 Study of Olverembatinib (HQP1351) in Patients With Chronic Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Product
olverembatinibClinical trial
A Phase 3, Multicenter, Randomized, Open-Label, Trial Evaluating the Efficacy and Safety of Asciminib Used in Consolidation With Imatinib v. Imatinib to Achieve Treatment-free Remission in Chronic Phase-Chronic Myelogenous Leukemia PatientsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
CASPALLO: A Phase I Study Evaluating the Use of Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2011-11-01
Product
Allodepleted T CellsClinical trial
A Pilot Study of Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Product
Darzalex FasproClinical trial
Venetoclax After TKI to Target Persisting Stem Cells in CMLStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase Ⅱ, Open Label, Single Arm, Single-Center Study to Evaluate the Efficacy and Safety of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsStatus: Completed, Estimated PCD: 2024-04-13
Clinical trial
Prospective Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Achieved Deep Molecular Response With Tyrosine Kinase Inhibitors in Real Life Setting in Argentina - (Argentine Stop Trial)Status: Recruiting, Estimated PCD: 2022-06-01
Product
Tyrosine Kinase InhibitorClinical trial
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance TherapyStatus: Completed, Estimated PCD: 2022-05-31
Product
Peginterferon α2bClinical trial
Frontline Asciminib Combination in Chronic Phase CMLStatus: Active (not recruiting), Estimated PCD: 2027-12-01
Clinical trial
Feasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACSStatus: Not yet recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Study of Efficacy and Safety of Long-acting Low Dose Ropeginterferon in Patients With Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis: a Randomized Prospective TrialStatus: Recruiting, Estimated PCD: 2024-02-01
Product
RopeginterferonClinical trial
CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant DiseaseStatus: Active (not recruiting), Estimated PCD: 2026-07-01
Drug
alemtuzumabProduct
MethylprednisoloneClinical trial
A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2010-11-01
Clinical trial
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior TransplantationStatus: Recruiting, Estimated PCD: 2024-07-01
Product
Anti-thymocyte globulinClinical trial
Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated DonorsStatus: Completed, Estimated PCD: 2011-08-01
Product
AlentuzumabProduct
Globulina antilinfocitariaProduct
HPC,AClinical trial
Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell TransplantationStatus: Completed, Estimated PCD: 2022-08-11
Drug
DocetaxelDrug
sirolimusClinical trial
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative RegimenStatus: Recruiting, Estimated PCD: 2024-12-31
Product
CyclosporineProduct
Mycophenolate SodiumClinical trial
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803Status: Completed, Estimated PCD: 2021-06-01
Product
Natural Killer CellsProduct
TreosulfanProduct
ALT803Clinical trial
Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideStatus: Recruiting, Estimated PCD: 2024-01-01
Product
EAGD T-cell infusionClinical trial
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) TrialStatus: Not yet recruiting, Estimated PCD: 2026-02-01
Product
EBX-102Clinical trial
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationStatus: Recruiting, Estimated PCD: 2025-01-01
Product
RuxolitinibClinical trial
Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell TransplantStatus: Recruiting, Estimated PCD: 2027-01-01
Product
PlaceboClinical trial
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular RemissionStatus: Active (not recruiting), Estimated PCD: 2026-06-01
Clinical trial
Asciminib as Single Agent or in Combination With Nilotinib in the 1st-line Treatment of BCR-ABL1+ Chronic Myeloid Leukemia: a Randomized GIMEMA-GELMC Phase II Study PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLStatus: Not yet recruiting, Estimated PCD: 2028-09-01
Clinical trial
The Efficacy and Safety of Third Generation Tyrosine Kinase Inhibitors Combined With Azacitidine and B-cell Lymphoma-2 Inhibitor in Patients With Myeloid Blast Phase Chronic Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Single-arm, Open-label, Multi-center Phase II Study Evaluating Efficacy and Safety of TGRX-678 in CML-AP Patients Relapsed or Refractory From 3rd-generation TKI TreatmentStatus: Not yet recruiting, Estimated PCD: 2026-07-15
Product
TGRX-678